cor2ed
engage checkpoint medical linkedin twitter
bg

Treating mCRPC patients who have progressed on AR-directed therapy

Treating mCRPC patients who have progressed on AR-directed therapy

Dr Fabio Schutz

Dr. Fabio Schutz addresses a key challenge when treating patients with metastatic castration resistant prostate cancer (mCRPC). What do you do if they progress on an androgen receptor (AR) directed therapy?
Portrait of Fabio Schutz
Dr Fabio Schutz

Medical Oncologist

Beneficencia Portuguesa de São Paulo

Brazil

preview next

time Expert View | open 5 min | Mar 2020

download resources

I agree that this educational programme:

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Other programmes of interest

Other programmes developed by Dr Fabio Schutz